01/12/2026
The MAR-Autism (MARAbio) test identifies a biologically defined subtype of autism known as Maternal Autoantibody-Related Autism (MARA).
In MARA, a mother produces IgG autoantibodies during pregnancy that target specific fetal brain proteins involved in neuronal development, synapse formation, and cortical organization. These antibodies can cross the placenta and interfere with brain development during critical windows.
This subtype has been associated with:
👉Higher likelihood of more severe autism presentations
👉Greater challenges with language, cognition, and adaptive functioning
👉A distinct immune-mediated developmental mechanism, not behavioral or environmental alone
This is not a diagnostic test for autism — it is a risk-stratification and mechanistic test that helps identify why autism may have developed in a subset of children.
Why this matters:
✅It moves autism out of a one-size-fits-all framework
✅It helps identify children whose autism has a prenatal immune origin
✅It informs clinical expectations, research-guided care, and future pregnancy planning
This is precision medicine for neurodevelopment — identifying biology, so we can better support these kids.
👉 Comment MARAbio if you’re interested in using this test.